Literature DB >> 33413223

High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.

Sicheng Zhou1, Qiang Feng1, Jing Zhang2, Haitao Zhou1, Zheng Jiang1, Zheng Liu1, Zhaoxu Zheng1, Haipeng Chen1, Zheng Wang1, Jianwei Liang3, Wei Pei4, Qian Liu1, Zhixiang Zhou1, Xishan Wang1.   

Abstract

BACKGROUND: This study aimed to evaluate the impact of postoperative complications on long-term survival in patients with peritoneal metastasis (PM) arising from colorectal cancer (CRC) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS: Patients with PM arising from CRC treated with CRS and HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. High-grade complications that occurred within 30 days were defined as grade 3 to 4 events according to the Common Terminology Criteria for Adverse Events (CTCAE) classification. Univariate and multivariable Cox regression models for overall survival were created. Predictors of high-grade postoperative complications were evaluated with univariate and multivariate logistic regression analyses.
RESULTS: In all, 86 consecutive cases were included in this study. Forty-one patients (47.7%) developed postoperative complications, while 22 patients (25.6%) experienced high-grade complications. No mortality occurred during the postoperative period. The median survival of all patients was 25 months, and the estimated 3-year overall survival (OS) rate was 35.0%. In the multivariable Cox regression analysis, a high peritoneal carcinomatosis index (PCI) score (HR, 1.07, 95% CI, 1.01-1.14; P=0.015) and grade 3-4 postoperative complications (HR, 1.86, 95% CI, 1.22-3.51; P=0.044) correlated with worse overall survival. High estimated blood loss (OR, 1.01, 95% CI, 1.01-1.02; P< 0.001) was identified as an independent risk factor for developing high-grade complications.
CONCLUSION: Careful patient selection, high levels of technical skill and improved perioperative management are crucial to ensure patient survival benefits after CRS+HIPEC.

Entities:  

Keywords:  Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Morbidity; Peritoneal metastasis; Prognostic factors

Mesh:

Year:  2021        PMID: 33413223      PMCID: PMC7791857          DOI: 10.1186/s12885-020-07756-7

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  35 in total

1.  Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.

Authors:  Lawrence Lee; Fanny Alie-Cusson; Pierre Dubé; Lucas Sideris
Journal:  J Surg Oncol       Date:  2017-04-13       Impact factor: 3.454

Review 2.  Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality.

Authors:  Terence C Chua; Tristan D Yan; Akshat Saxena; David L Morris
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

3.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

Authors:  M Bushati; K P Rovers; A Sommariva; P H Sugarbaker; D L Morris; Y Yonemura; C A Quadros; S P Somashekhar; W Ceelen; P Dubé; Y Li; V J Verwaal; O Glehen; P Piso; J Spiliotis; M C C Teo; S González-Moreno; P H Cashin; K Lehmann; M Deraco; B Moran; I H J T de Hingh
Journal:  Eur J Surg Oncol       Date:  2018-07-20       Impact factor: 4.424

4.  Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.

Authors:  G Lorimier; B Linot; N Paillocher; D Dupoiron; V Verrièle; R Wernert; A Hamy; O Capitain
Journal:  Eur J Surg Oncol       Date:  2016-10-07       Impact factor: 4.424

5.  Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis.

Authors:  Ju-Li Koh; Tristan D Yan; Derek Glenn; David L Morris
Journal:  Ann Surg Oncol       Date:  2008-12-03       Impact factor: 5.344

6.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

7.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

Authors:  Dominique Elias; François Gilly; Florent Boutitie; François Quenet; Jean-Marc Bereder; Baudouin Mansvelt; Gérard Lorimier; Pierre Dubè; Olivier Glehen
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review.

Authors:  Eliza W Beal; Lorena P Suarez-Kelly; Charles W Kimbrough; Fabian M Johnston; Jonathan Greer; Daniel E Abbott; Courtney Pokrzywa; Mustafa Raoof; Byrne Lee; Travis E Grotz; Jennifer L Leiting; Keith Fournier; Andrew J Lee; Sean P Dineen; Benjamin Powers; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; Harveshp Mogal; Marti C Russell; Mohammed Y Zaidi; Sameer H Patel; Vikrom Dhar; Laura Lambert; Ryan J Hendrix; John Hays; Sherif Abdel-Misih; Jordan M Cloyd
Journal:  J Clin Med       Date:  2020-03-10       Impact factor: 4.241

10.  The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Jolene Si Min Wong; Grace Hwei Ching Tan; Claramae Shulyn Chia; Johnny Ong; Wai Yee Ng; Melissa Ching Ching Teo
Journal:  World J Surg Oncol       Date:  2020-01-13       Impact factor: 2.754

View more
  2 in total

1.  Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Authors:  Haipeng Chen; Sicheng Zhou; Jianjun Bi; Qiang Feng; Zheng Jiang; Jianping Xu; Wei Pei; Jianwei Liang; Zhixiang Zhou; Xishan Wang
Journal:  World J Surg Oncol       Date:  2021-08-26       Impact factor: 2.754

2.  The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis.

Authors:  Oleksandr Vadymovych Bondar; Serhii Hennadiiovych Chetverikov; Viacheslav Yevheniiovych Maksymovskyi; Dmytro Vadymovych Atanasov; Valeriia Volodymyrivna Chetverikova-Ovchynnyk; Mykhailo Serhiiovych Chetverikov
Journal:  Contemp Oncol (Pozn)       Date:  2021-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.